Cinryze

Jefferies & Company analysts Thomas Wei, Shaunak Deepak and Thomas Nguyen rated shares of ViroPharma Incorporated (Nasdaq: VPHM) a Buy and raised the price target from $16 to $18. The analysts said that there were a number of ways ViroPharma Incorporated would benefit from health care reform....